Javier Cervantes-Bojalil

Gastrointestinal oncology

[Javier Cervantes-Bojalil @javiercboj]

LATAM Oncology Summit 2025 - Cáncer colorrectal.

[Oscar Tahuahua @drtahuahua]

Multidimensional differences in Right vs Left sided Colorectal Ca

R & L CRC differ in tumor biology, clinical behavior & response to targeted therapy

Shifting from sidedness to molecular classification may better guide treatment decisions @OncoAlert
https://t.co/jf7fTbybPg

[Arndt Vogel @ArndtVogel]

Expanding the potential of antibody drug conjugates in gastrointestinal malignancies: beyond HER2 targets
@ESMO_Open
https://t.co/0vFQ5kemVh
👏Excellent review on ADCs
👉comprehensive review on MOA, resistance mechanism, old & new targets and future directions
@myESMO

[Josette Staufert @Staufertjr]

Kidney cancer causes over 150,000 deaths per year worldwide 🌎

Here are a few tips to help prevent it:

1. Don’t smoke 🚭
2. Maintain a healthy weight ⚖️
3. Control blood pressure 🫀
4. Limit alcohol 🍸
5. Healthy diet 🥬
6. Exercise regularly 🏃🏻‍♀️
7. Regular health checkups 👩🏻‍⚕️

[Arndt Vogel @ArndtVogel]

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY- Gastric04 Phase 3 Trial
👉ENHERTU more effective than Pacli/Ram
https://t.co/TOduG8XVv3
@myESMO

[Science Magazine @ScienceMagazine]

Early-onset colorectal cancer is expected to become the leading cause of #cancer death in ages 20 to 49 in the U.S. by 2030.

Research is urgently needed to better detect and treat patients, argues this #SciencePerspective: https://t.co/3hkt8o9YZE #ColorectalCancerAwarenessMonth

[Vinod BalachandranMD @TheVinodLab]

#mRNAvaccines for #PancreaticCancer (PDAC) PART4

1. Out today in @Nature https://t.co/NhpkJeaQYb

🧵👇🏽

[1/23]

[Elvina Almuradova @Dr_ElvinaA]

Our latest review on KRAS mutations in early-stage colorectal cancer is out! 🧬

We discuss their prognostic impact, and highlight the importance of routine molecular profiling for better risk stratification and adjuvant therapy decisions.

https://t.co/77I81QcUYt

[Erman Akkus @Erman_Akkus]

💉Neoadjuvan ChT in colon cancer
@ASCO

➡️@AmericanCancer database
✅OS benefit in T4 tumors
❌But not in T3

👉https://t.co/8ffaUXknDS

@OncoAlert #cancer #oncology #MedX

[Angela Lamarca @DrAngelaLamarca]

Hot off the press 🔥
Our views on current management of #advanced #HCC at @myesmo ESMO Gastrointestinal Oncology 📖

📝Summary of current studies
👉Factors for treatment selection

@LorenzaRimassa @DJPinato @AndreaMartirena @Hospital_FJD @GrupoTTD

https://t.co/RLT26pMRtb

[TIME @TIME]

More young adults are getting cancer. Researchers are racing to understand why https://t.co/kWNG4J5U7j

[Oscar Tahuahua @drtahuahua]

Total neoadjuvant treatment, Non-operative management and Radiotherapy-free strategies: New approaches for the management of pMMR/MSS locally advanced rectal cancer.

A comprehensive review and evidence-based algorithm

https://t.co/gMAwbmuXiq

[#TumorBoardTuesday @TumorBoardTues]

#TumorBoardTuesday
🤔Can Claudin 18.2 be used for Tx💊outside of upper GI Ca❓

📢Join us Tuesday, 02-04-25 at 8PM ET as @ndevitomd & @KatherineZhouMD from @DukeMedSchool 🗣️Claudin 18.2 as a🎯in #pancreaticcancer

RT and bring others into the discussion‼️

[Dr. Nina Niu Sanford @NiuSanford]

A 33 min overview of GI rad onc!

I made this video for an oral boards review course, sharing here.

It’s just 5 slides (below) & me talking the whole time, so you can just listen.

Hope it’s helpful! Link next post, and short 🧵.

[Erman Akkus @Erman_Akkus]

📘Treatment of dMMR/MSI gastro-oesophageal adenocarcinoma
@myESMO @EORTC

✅Excellent review from biology to management

👉https://t.co/AzSfSgCixG

@LizzySmyth1 @AngelicaSSophie @OncoAlert #cancer #oncology #MedX

[Instituto Nacional de Cancerología @incanMX]

04 de febrero | Día Mundial contra el Cáncer

En este Día Mundial contra el Cáncer, unámonos para reescribir el futuro de la atención oncológica, un futuro en el que las necesidades de las personas y las comunidades sean lo primero.

#UnidosPorloÚnico

[Erman Akkus @Erman_Akkus]

🧫Cell-Based Therapies in GI Cancers
@ASCO

✔️Still long way to go but have a potential

👉https://t.co/ZiTkp5wad6

@OncoAlert @JCOPO_ASCO #cancer #oncology #MedX

[Arndt Vogel @ArndtVogel]

Trastuzumab with or without pertuzumab for peri-op CTx of HER-2+ GC #ASCOGI25
🔎EORTC-1203 GITC INNOVATION
👉mpRR: 23 vs 37 vs 26%
👉3yr OS rate: 75 vs 76 vs 65%
👉High Tox for CTx + T + P
🧐 Negative trial, but high mpRR by adding T to CTx
@myESMO

[Javier Cervantes-Bojalil @javiercboj]

That is an excellent point and some food for thought: if pCR is not a good surrogate for survival in GE cancers, what endpoints should we assess, and how should we design future clinical trials?

[Dr Amol Akhade @SuyogCancer]

The reason why PCR is a soft end point in Gastro Esophageal cancer. Especially in studies involving CTRT . Are we chasing the wrong goal post . #GI25 . @ASCO @NiuSanford @KrishanJethwa @5_utr @Larvol

[Annals of Oncology @Annals_Oncology]

🆕article in press: The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study @e_rangelova; @TFStoop; @TessvRamshorst; @MarcBesselink; @chiaro_del; @e_mips; @CUpancreas;
@CancerCenterAms
https://t.co/OLOLaoOYFL